

AMENDMENTS TO THE SPECIFICATION

On page 40, lines 7 to 14, please delete the paragraph beginning, "Figure 16. *In vivo* effect of the human anti-DR mAb . . .", and replace it with the following new paragraph:

--Figure 16. Figures 16A-E show the *in vivo* effect of the human anti-DR mAb 1D09C3 in lymphoma xenograft models.

Figure 16A shows survival of SCID mice injected s.c. with the non-Hodgkin lymphoma line GRANTA-519. MAb dose was 3x1 mg/mouse given on days 5, 7, and 9. Seven mice in the control and five in each mAb treated group.

Figure 16B shows the effect of mAb on subcutaneous tumor growth. Same experiment as in Figure 16A.

Figure 16C shows the effect of mAb on disease incidence in SCID mice injected i.v. with GRANTA-519. MAb was administered i.v., 3x as above. Six mice were in each group.

Figure 16D shows representative tumor size in untreated mice.

Figure 16E shows representative tumor size in mice treated with mAb.--